This story has been updated to include comments from a company official.

By Justin Petrone

Signal Genetics and DiagnoCure this week announced a collaboration arrangement valued at $13.3M over the first five years.

Under the terms of the agreement, Signal Genetics acquired DiagnoCure's US Clinical Laboratory Improvement Amendments-compliant service laboratory and was granted a worldwide exclusive license to its Previstage GCC Colorectal Cancer Staging Test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.